Kristine Ivanova

Dr. Kristine Ivanova

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
KIKristine Ivanova
Kristine Ivanova
MZMaksims Zolovs
Maksims Zolovs
KBKaj Blennow
Kaj Blennow
HZHenrik Zetterberg
Henrik Zetterberg
NKNataļja Kurjāne
Nataļja Kurjāne
NANata
Nata
Introduction: Systemic sclerosis (SSc) is a rare autoimmune disease with multiple organ involvement; however, the contribution of the nervous system (NS) remains relatively understudied. There are no specific data on the role of the autoimmune response and inflammation in the development of peripheral nerve system (PNS) damage in SSc and markers to assess this damage have yet to be identified.Objectives: The primary objective of this study was to define the autoimmune mechanisms that lead to neuropathy by identifying antibodies (Abs) that target certain component of the NS or are associated with SSc. The secondary objective was to identify markers of NS damage that correlate with the detection and progression of polyneuropathy (PNP).Methods: This study included patients diagnosed with SSc who met ACR/EULAR 2013 classification criteria at two leading Latvian hospitals between January 2016 and December 2021. Patients underwent a nerve conduction study (NCS). The SSc-associated Abs, Abs against myelin-associated glycoprotein (MAG) and anti-ganglioside Abs (GM1, GM2, GD1a, GD1b and GQ1b) were analysed. Potential serum PNS biomarkers—neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), fibroblast growth factor 21 (FGF21) and growth/differentiation factor 15 (GDF15)—were measured.Results: We recruited 103 Caucasian patients diagnosed with SSc. SSc-associated Abs did not differ significantly between patients with and without PNP (p > 0.05). Anti-MAG and anti-ganglioside Abs in patients with PNP did not present a significant increase above the reference range. NfL, GFAP and GDF15 were significantly elevated in the presence of PNP (p < 0.05), with a moderate to high effect size (r = 0.36–0.65). Our regression analysis revealed a strong association between the HAQ-DI score, older age, male gender and the risk of developing PNP.Conclusion: The development of PNP in patients with SSc is most likely due to ageing, natural progression and the sequelae of the disease. Several serum biomarkers—NfL, GFAP and GDF15—could be used as relevant diagnostic biomarkers for PNP in patients with SSc. Future studies are warranted to validate the diagnostic efficacy of these biomarkers and to unravel the complex interplay of factors leading to PNP in patients with SSc.

1 October 2016 in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Verified
Journal Article
Open access
PDF file
KIKristine Ivanova
Kristine Ivanova
MAMarija Avota
Marija Avota
Due to their adverse effects, antineoplastic drugs (cancer chemotherapy drugs) are considered as a potential health risk for nurses and nursing assistants. The aim of this study was to review and summarise information about acute side effects of antineoplastic drugs in two major cancer centres in Latvia. In total 51 nurses and nursing assistants participated in the study, all working in chemotherapy ward at least for 12 months. The research was conducted in Pauls Stradiņš Clinical University Hospital and Rīga East University Hospital, Oncology Centre of Latvia. 56.86% of respondents reported at least one side effect since working in the department of chemotherapy (DC). Headache was the most common acute side effect (37.25%), followed by irritation of eyes (25.49%) and irritation of skin (19. 60%). Headache (p = 0.021), dizziness (p = 0.018), irritation of mouth and throat (p = 0.043), and irritation of eyes (p = 0.004) had statistically significant positive association with years of working in DC, suggesting that those working for longer time in DC are more likely to have headache, dizziness, irritation of mouth, throat and eyes

30 September 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
KIKristine Ivanova
Kristine Ivanova
OROlga Ribakova
Olga Ribakova
AMAnna Mihailova
Anna Mihailova
EMEvelina Mozeitovica
Evelina Mozeitovica
AKAnda Kadisa
Anda Kadisa
IBInita Bulina
Inita Bulina
Background: Systemic sclerosis (SSc) is considered by many to be one of the most severe autoimmune rheumatic diseases with lower prevalence observed in Northern Europe. No previous studies on the prevalence of SSc in Latvia have been conducted and the aim was to study the demographic and clinical data of patients with SSc in northeastern Europe country. Methods: This study was conducted in two main Latvian hospitals for adults and includes patients with SSc who were consulted between 2016 and 2021. Results: During the study period, 159 patients with SSc were consulted. The point prevalence on 1 January 2021 was 84.0 per million. Female to male ratio was 4.67:1, and highest gender ratio was observed in the age group 70–79-year (6.75:1). Antinuclear antibodies were present in 82.58% of patients, without gender difference. Centromere pattern was more frequently observed in females (40.19% vs. 19.04%), in contrast to speckled pattern (50.98% vs. 57.14%). At disease onset females tended to be younger (46.51 ± 13.52) than males (50.5 ± 16.64). Males had more diffuse cutaneous subtype, interstitial lung disease, pulmonary hypertension and esophageal dysmotility. More than half of patients received treatment with glucocorticoids at any point of the disease (68.31%), without gender difference. Conclusions: Systemic sclerosis is less common in Latvia than in other countries and regions. Due to its location, the data from Latvia are consistent with a north-south gradient in Europe. Gender ratio differences persisted in older age groups as well. Antinuclear antibodies presence did not differ between genders, but in female’s centromere pattern was much more likely to be present. Males had more severe disease course, but in both genders more than half of patients received treatment with GCs at any point of the disease.

Verified
Journal Article
Open access
PDF file
KIKristine Ivanova
Kristine Ivanova
TSTheresa Schiemer
Theresa Schiemer
AVAnnija Vaska
Annija Vaska
NKNatalja Kurjane
Natalja Kurjane
VKViktorija Kenina
Viktorija Kenina
KKKristaps Klavins
Kristaps Klavins
Metabolome studies have already been carried out in patients with systemic sclerosis (SSc). However, polyneuropathy (PNP) as a complication of SSc has been overlooked in these studies. To the best of our knowledge, this is the first study to examine metabolic changes in SSc patients with PNP. Patients with SSc (n = 62) and a healthy control group (HC) (n = 72) were recruited from two Latvian hospitals. Blood plasma samples were collected and analyzed using an LC-MS-based targeted metabolomics workflow. Our plasma sample cohort consisted of 62 patients with SSc, 42% of whom had PNP. Differences between SSc patients and the HC group with fold changes > 2 were observed for aspartic acid, glutamic acid, valine, and citrulline, all of which were reduced. In contrast to the SSc to HC discrimination, no metabolites had a high fold change; only minor changes were observed using FC > 1.3. We identified elevated concentrations of kynurenine, asparagine, and alanine. Changes in metabolite regulation in patients with SSc, compared to controls, are not identical to those observed in SSc patients with PNP, with elevated concentrations of kynurenine and alanine specific to the SSc subgroup. SSc patients with PNP should probably be considered a distinct population with important metabolomic features.

5 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
KIKristine Ivanova
Kristine Ivanova
OROlga Ribakova
Olga Ribakova
AMAnna Mihailova
Anna Mihailova
EMEvelina Mozeitovica
Evelina Mozeitovica
AKAnda Kadisa
Anda Kadisa
IBInita Bulina
Inita Bulina
Background Systemic sclerosis (SSc) is considered by many to be one of the most severe autoimmune rheumatic diseases with lower prevalence observed in Northern Europe. No previous studies on the prevalence of SSc in Latvia have been conducted and the aim was to study the demographic and clinical data of patients with SSc in northeastern Europe country. Methods This study was conducted in two main Latvian hospitals for adults and includes patients with SSc who were consulted between 2016 and 2021. Results During the study period, 159 patients with SSc were consulted. The point prevalence on 1 January 2021 was 84.0 per million. Antinuclear antibodies were present in 82.58% of patients, equally in females (82.81%) and in males (81.41%). Centromere pattern was more frequently observed in females than in males (40.19% vs 19.04%), while speckled pattern was the most frequently observed pattern in both genders (50.98% vs 57.14%). At disease onset females tended to be younger (46.51 ± 13.52) than males (50.5 ± 16.64). More than half of patients received treatment with glucocorticoids at any point of the disease (68.31%). Conclusions Systemic sclerosis is less common in Latvia than in other countries and regions. Due to its location, the data from Latvia are consistent with a north-south gradient in Europe. ANA presence did not differ between genders, but in females centromere pattern was much more likely to be present. More than half of patients received treatment with GCs at any point of the disease.

13 May 2026
Verified
Thesis
Open access
PDF file
KIKristine Ivanova
Kristine Ivanova
Sistēmiskā skleroze (SSc) ir reta sistēmiska saistaudu slimība (ORPHA kods 90291) un viena no smagākajām autoimūnām reimatiskām slimībām, ar 3,5 reižu augstākiem mirstības rādītājiem nekā tāda paša vecuma veseliem indivīdiem. Saslimstība un izplatība ievērojami atšķiras starp reģioniem, Ziemeļeiropā slimību novēro retāk, bet Latvijas dati līdz šim nav publicēti. Perifērās nervu sistēmas (PNS) iesaiste SSc gadījumā joprojām ir nepietiekami raksturota, un tās patoģenēze nav skaidra. Lai gan galvenā hipotēze ir išēmiska, iespējams, ka ir iesaistīti arī citi mehānismi. Serumā konstatējamās autoantivielas ir SSc raksturīga pazīme, tomēr nav pierādīta to saistība ar PNS bojājumu. Potenciālie biomarķieri – neirofilamentu vieglās ķēdes (NfL), augšanas/diferenciācijas faktors 15 (GDF15), glijas fibrillārais skābais proteīns (GFAP) un fibroblastu augšanas faktors 21 (FGF21) – tika analizēti citu slimību gadījumos, tomēr ar SSc saistītās polineiropātijas (PNP) gadījumā plaši nav pētīti. Tāpat metaboloma pētījumi SSc gadījumā līdz šim nav pievērsušies PNP. Šī pētījuma mērķis bija noteikt SSc izplatību Latvijā, salīdzināt to ar starptautiskiem datiem, aprakstīt demogrāfiskās un klīniskās īpatnības ar uzsvaru uz PNS iesaisti, izpētīt patoģenēzi un novērtēt potenciālos biomarķierus. Analizēti dati no abām Latvijas pieaugušo klīniskajām universitātes slimnīcām, kurās nonāk praktiski visi pacienti ar aizdomām par SSc. Identificēti 159 pacienti, kas atbilda ACR/EULAR 2013 kritērijiem laika posmā no 2016. līdz 2021. gadam. SSc prevalence 84,0 (95 % CI 71,9–98,1) uz miljonu iedzīvotāju, augstākais rādītājs bija 60–69 gadu vecuma grupā. Sieviešu un vīriešu attiecība bija 4,67:1, sievietes tika diagnosticētas nedaudz vēlāk kā vīrieši (63,12 pret 59,75 gadiem). Lielākā daļa bija ANA pozitīvi (82,58 %), ar dominējoši plankumveida un anticentromēru (ACA) paterniem; ACA biežāk sastopamas sievietēm, bet anti-topoizomerāzes I (ATA) antivielu biežums neatšķīrās starp dzimumiem. Pirmie simptomi, kas nebija saistīti ar Reino fenomenu, parasti parādījās piektajā dzīves desmitgadē. Sievietēm slimība sākās agrāk nekā vīriešiem (46,51 ± 13,52 pret 50,5 ± 16,64 gadiem). Neskatoties uz nelielo vīriešu skaitu (n = 18), vērojās tendence uz smagāku slimības gaitu ar augstāku intersticiālās plaušu slimības (ILD), plaušu hipertensijas (PH) un barības vada dismotilitātes biežumu. Glikokortikoīdus lietoja 68,31 % pacientu – visbiežāk pie difūzas ādas SSc formas (90 %), bet arī limitētas (70,59 %) un sine scleroderma (66,67 %) gadījumos. Tika izvērtēta PNS iesaiste. Lielo šķiedru neiropātija (LFN) tika konstatēta 43 % no 100 pacientiem, kuriem veikta neirogrāfija (NCS). No 57 pacientiem bez NCS izmaiņām 38 tika veikta kvantitatīvā sensorā testēšana (QST), atklājot smalko šķiedru neiropātiju (SFN) 29 gadījumos. Neiropātiskas sāpes bija 40,59 % pacientu, biežāk LFN grupā (47,62 %) nekā bez LFN (35,59 %). Neiropātisko sāpju intensitāte korelēja ar kopējo neiropātijas punktu skaitu (srTNS) (r = 0,51, p < 0,001), trauksmainību (r = 0,61, p < 0,001) un sliktāku ar veselību saistītu dzīves kvalitāti (HRQoL) (r = 0,39, p = 0,001). Autoantivielu analīzē, stratificējot pēc PNP klātbūtnes, visbiežāk konstatētās antivielas bija ACA (36,08 %), ATA (22,68 %) un anti-Ro52 (22,68 %). Neviena antiviela nebija statistiski nozīmīgi saistīta ar PNP, lai gan anti-Ro52 novēroja aizsargājoša faktora tendenci. Antivielas pret mielīna asociēto glikoproteīnu un gangliozīdiem nebija saistītas ar PNP. Seruma biomarķieru līmeņi PNP pacientiem bija būtiski augstāki: NfL (r = 0,62, p < 0,001), GFAP (r = 0,36, p = 0,011) un GDF15 (r = 0,65, p < 0,001), savukārt FGF21 atšķirību neuzrādīja. Metabolomiskajā profilā SSc pacientiem, salīdzinot ar veselo kontroli, tika konstatēts samazināts asparagīnskābes, glutamīnskābes, valīna un citrulīna līmenis (> 2 reizes), kā arī paaugstināts glutamīna līmenis (> 1,5 reizes). Salīdzinot SSc pacientus ar un bez PNP, neviens metabolīts nesasniedza diskriminācijas slieksni; lietojot zemākus sliekšņus, PNP pacientiem tika konstatēts paaugstināts kinurenīna un alanīna līmenis un samazināta asparagīnskābe, savukārt asparagīna samazinājums bija kopīgs gan pacietiem ar PNP, gan bez PNP. Kinurenīna un alanīna izmaiņas bija raksturīgas tikai SSc pacietiem ar PNP. Secinājumā, SSc izplatība Latvijā ir zemāka nekā...